Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer.
Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer.
复制标题
DOI：
10.18926/amo/46848
复制
发表时间：
2011-08
影响因子：
0.5
通讯作者：
T. Shien;H. Doihara;Keiko Nishiyama;H. Masuda;T. Nogami;Hirokuni Ikeda;N. Taira
中科院分区：
文献类型：
--
作者：
T. Shien;H. Doihara;Keiko Nishiyama;H. Masuda;T. Nogami;Hirokuni Ikeda;N. Taira
口服卡培他滨（希罗达）和环磷酰胺（XC）的低剂量联合治疗已被证明对转移性乳腺癌（MBC）患者的病变长期控制有效，旨在缓解症状和延长生存期。在此，对在冈山大学医院（OUH）接受XC的MBC患者进行回顾性分析，以评价对XC的反应、不良事件和至进展时间（TTP）。2006年至2009年间，20名MBC患者接受了XC治疗。除2例在初次检查时年龄超过70岁的老年患者外，所有患者既往均接受过蒽环类和/或紫杉烷类药物治疗。未观察到完全缓解（CR）病例，但部分缓解（PR）6例（30%），SD 9例（45%），其中5例（20%）持续SD状态>12个月。中位TTP为6个月（范围：3-27个月）。3例患者发生3级不良事件（腹泻、恶心和口腔炎），但没有其他患者发生导致治疗中断的不良反应。XC是安全的，即使在以前治疗和老年MBC患者，而且，它产生了显着的临床反应。
Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival. Here, a retrospective review was conducted of MBC patients administered XC at the Okayama University Hospital (OUH), to evaluate responses to XC, adverse events and time to progression (TTP). Twenty patients with MBC received XC between 2006 and 2009. With the exception of 2 elderly patients who were over the age of 70 at the initial examination, all of the patients had received prior treatment with an anthracycline and/or a taxane. No complete response (CR) cases were observed, but partial response (PR) was achieved in 6 patients (30%) and SD in 9 (45%), of whom 5 (20%) sustained SD status for >12 months. The median TTP was 6 months (range:3-27 mo.). Three patients developed Grade 3 adverse events (diarrhea, nausea and stomatitis), but no other patients developed adverse reactions causing interruption of the therapy. XC was safe even in previously treated and elderly MBC patients;moreover, it yielded remarkable clinical responses.